The distribution and excretion of 14C- and 3H-labelled 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in the rat.
The distribution and excretion of radioactivity following a single or multiple oral administration of 3H-and/or 14C-4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) has been determined in rats. The daily excretion of radioactivity following a single administration (3H and 14C) or multiple doses (3H) fell to less than 1% of the dose in 4 days. A similar fall was observed at the end of 10 days continuous administration. The radioactivity in plasma reached a maximum between 2 and 4 h after administration of the drug (14C). Tissue levels were found to be effectively zero 24 h after administration of the drug for up to 10 days. The very large amounts of radioactivity lost in bile were found to correlate with blood, tissue and faecal levels.
D000284:Administration, Oral; D000818:Animals; D001646:Bile / Q000378:metabolism; D002250:Carbon Radioisotopes; D005260:Female; D011298:Feprazone / Q000008:administration & dosage / Q000378:metabolism*; D007553:Isotope Labeling; D007700:Kinetics; D008297:Male; D010653:Phenylbutazone / Q000031:analogs & derivatives*; D051381:Rats; D012737:Sex Factors; D014316:Tritium
D002250:Carbon Radioisotopes; D014316:Tritium; D011298:Feprazone; D010653:Phenylbutazone